Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.
Reprod Biol Endocrinol. 2023 Jan 30;21(1):13. doi: 10.1186/s12958-023-01069-7.
Ovarian stimulation (OS) is one of the key factors in the success of in vitro fertilization-embryo transfer (IVF-ET), by enabling the recruitment of numerous healthy fertilizable oocytes and, thereby, multiple embryos. The Stop GnRH-agonist/GnRH-antagonist (GnRH-ag/GnRH-ant), which offers all the advantages of using long suppressive GnRH-ag, with GnRH-ant, is in my opinion a valuable addition to the armamentarium of OS protocols. It allows cycle programming, better follicular synchronization and offers successful outcome in a variety of challenging cases such as poor responders, Poseidon group 4 poor prognosis patients, those with elevated peak progesterone (P) serum levels, poor embryo quality or repeated IVF failures.
卵巢刺激(OS)是体外受精-胚胎移植(IVF-ET)成功的关键因素之一,它可以募集大量健康的可受精卵子,并由此产生多个胚胎。我认为,使用长效抑制 GnRH-激动剂(GnRH-ag)联合 GnRH 拮抗剂(GnRH-ant)的 Stop GnRH-agonist/GnRH-antagonist(GnRH-ag/GnRH-ant)是 OS 方案中的一种有价值的补充,它具有 GnRH-ag 的所有优势,能够进行周期编程,更好地同步卵泡,并在各种具有挑战性的情况下取得成功,如卵巢反应不良、Poseidon 分组 4 预后不良的患者、血清孕激素(P)峰值升高、胚胎质量差或反复 IVF 失败的患者。